Word

RHEACELL INNOVATIVE STEM CELL THERAPIES

Status

Registered

Status Code

700

Status Date

Tuesday, April 12, 2022

Serial Number

79307004

Registration Number

6696110

Registration Date

Tuesday, April 12, 2022

Mark Type

4000

Filing Date

Friday, December 11, 2020

Published for Opposition

Tuesday, January 25, 2022

Trademark Owner History

RHEACELL GmbH & Co. KG - Original Registrant

Classifications

5 Drugs, namely, drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical and veterinary preparations for the treatment of skin diseases, pharmaceutical and veterinary preparations for the treatment of vertigo, pharmaceutical and veterinary preparations for the treatment of nausea, pharmaceutical and veterinary preparations for the treatment of vomiting, pharmaceutical and veterinary preparations for the treatment of migraine, pharmaceutical and veterinary preparations for the treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system, pharmaceutical and veterinary preparations for the treatment of blood diseases and disorders, pharmaceutical and veterinary preparations, namely, antibiotics, immune suppressants, anti-inflammatory preparations, pharmaceutical and veterinary preparations for wound healing, pharmaceutical and veterinary preparations for anti-aging, namely, stem cells for medical and medical aesthetic purposes, fibroblast cells for medical and medical aesthetic purposes, surgical tissue implants comprised of living tissues obtained from fibroblasts; diagnostic agents for medical purposes; diagnostic preparations for medical and biomedical purposes; pharmaceutical cell preparations for medical use for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, disease and disorders of the reproductive system, blood diseases and disorders; sterilizing substances for medical use; sterilizing substances for biomedical purposes; live implants comprising of live tissues for pharmaceutical purposes; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for medical use; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for pharmaceutical purposes; biochemical and chemical products for pharmaceutical or medical purposes, namely, biochemical preparations for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, and disease and disorders of the reproductive system, blood diseases and disorders for diagnostic purposes; proteins being protein supplements for medical purposes; biological preparations for medical and veterinary purposes, and pharmaceutical and veterinary preparations, all for external use for the treatment of skin diseases, wounds, ulcers, burns and surgical wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes; medical dressings; pharmaceutical preparations for wound treating and healing; biological, pharmaceutical and veterinary preparations for the treatment of chronic wounds, ulcers, burns and surgical wounds; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes for medical use; somatic stem cell therapeutics for medical purposes; pharmaceutical implants, namely, implantable surgery human allograft bones, biological bone tissue grafts, cells for medical use, biological bone marrow tissue; surgical implants comprised of living stem cells; surgical implants comprised of living fibroblasts tissue cells; biological human skin and bone tissue intended for subsequent implantation; cell growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, vascular grafts; biotechnologically engineered tissue products, namely, tissue cells in sheet form and plasters for wound healing and treating burns for medical purposes, biological eye lens tissue grafts, biological bone tissue grafts

44 Medical services; medical diagnostic services for carrying out tests and analyses; medical assistance; medical clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, stem cell therapy for treating medical conditions; medical services being human cells and tissue banks, stem cell banks and bone marrow banks, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services being banks of human tissue and stem cells, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services in the nature of stem cell banks for medical transplantation; medical services in the nature of cultured stem cell banks for medical transplantation

42 Pharmaceutical drug development; scientific and technological services, namely medical and pharmaceutical research services and technical research in the field of pharmaceutical studies, regenerative medicine and tissue engineering; research and development services in the fields of cell diagnostics and research and development services relating to new products for others in the field of therapy and surgical and medical instruments; industrial analysis and research services, namely analysis of industrial fluids and medical research, chemical analysis; scientific research for medical purposes in the field of stem cell therapies; stem cell research; scientific and medical research and development in the field of stem cells; scientific research, testing and analysis services of the services of others to determine conformity with certification standards and in the field of regenerative medicine and tissue engineering; scientific research for medical purposes; medical research; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; product research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology

RHEA CELL INNOVATIVE STEM CELL THERAPIES
"INNOVATIVE STEM CELL THERAPIES"

Trademark Events

Sep 20, 2022

Final Decision Transaction Processed By Ib

Aug 26, 2022

Final Disposition Notice Sent To Ib

Aug 26, 2022

Final Disposition Processed

Jul 12, 2022

Final Disposition Notice Created, To Be Sent To Ib

Apr 12, 2022

Registered-Principal Register

Jan 25, 2022

Official Gazette Publication Confirmation E-Mailed

Jan 25, 2022

Published For Opposition

Jan 22, 2022

Notification Processed By Ib

Jan 5, 2022

Notification Of Possible Opposition Sent To Ib

Jan 5, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jan 5, 2022

Notification Of Notice Of Publication E-Mailed

Dec 21, 2021

Approved For Pub - Principal Register

Dec 21, 2021

Examiner's Amendment Entered

Dec 21, 2021

Notification Of Examiners Amendment E-Mailed

Dec 21, 2021

Examiners Amendment E-Mailed

Dec 21, 2021

Examiners Amendment -Written

Dec 7, 2021

Teas/Email Correspondence Entered

Dec 6, 2021

Correspondence Received In Law Office

Dec 6, 2021

Teas Response To Office Action Received

Jun 28, 2021

Refusal Processed By Ib

Jun 9, 2021

Non-Final Action Mailed - Refusal Sent To Ib

Jun 9, 2021

Refusal Processed By Mpu

Jun 8, 2021

Non-Final Action (Ib Refusal) Prepared For Review

Jun 7, 2021

Non-Final Action Written

Jun 3, 2021

Assigned To Examiner

Mar 26, 2021

Application Filing Receipt Mailed

Mar 22, 2021

New Application Office Supplied Data Entered In Tram

Mar 18, 2021

Sn Assigned For Sect 66a Appl From Ib